Key insights
- Director Ronda E. Stryker sold approximately $96.8 million in company shares, a significant insider transaction. This occurs despite the stock's recent underperformance and a Q1 earnings miss due to a cyber incident. While the company reaffirmed guidance and analysts maintain buy ratings, the large sale by a director, coupled with operational disruptions and a reduced price target, suggests potential near-term headwinds for Stryker Corp, which could have a minor negative influence on the broader healthcare equipment sector.
Ronda E. Stryker, a director at medical technology company Stryker Corp (NASDAQ:SYK), sold 300,000 shares of common stock on May 26, 2026, for a total value of approximately $96.8 million. The shares were disposed of at prices ranging from $310.77 to $315.114 per share. The sale comes as the stock trades at $307.52, down nearly 19% over the past year, though the company maintains its position as a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $117.3 billion.
The transactions were conducted indirectly through a revocable trust. Following these sales, the revocable trust holds 2,600,815 shares of Stryker Corp common stock. This figure includes 679,642 shares that were transferred to the revocable trust from the L. Lee Stryker Trust on May 28, 2026.
Ms. Stryker also indirectly holds 12,177,521 shares through the L. Lee Stryker Trust and 37,600 shares through the 1988 William D. Johnston Trust. Additionally, she directly holds 1,322 shares of Stryker Corp common stock.According to InvestingPro analysis, Stryker appears undervalued at current levels based on Fair Value calculations. Investors seeking deeper insights can access comprehensive analysis through InvestingPro, including 10 additional ProTips and detailed Pro Research Reports covering this and 1,400+ other US equities.
In other recent news, Stryker Corporation reported its Q1 2026 earnings, which were significantly impacted by a cyber incident that disrupted operations. The company missed earnings and revenue forecasts, posting an EPS of $2.60 compared to the anticipated $2.98, and revenue of $6 billion, falling short of the expected $6.34 billion. Despite this setback, Stryker reaffirmed its 2026 guidance. In response to the cyberattack’s impact, Argus adjusted its price target for Stryker shares from $435 to $350, though it maintained a Buy rating on the company. Additionally, Stryker’s shareholders re-elected all ten members of the board of directors during the recent annual meeting. The board also declared a quarterly dividend of $0.88 per share, marking a 4.8% increase from the previous year, with the payment scheduled for July 31, 2026. These developments highlight ongoing challenges and strategic decisions for Stryker as it navigates the effects of the cyber incident.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for SYK plus thousands of other stocks and find your next hidden gem with massive upside.